These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11395133)

  • 1. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein.
    Meng WS; Butterfield LH; Ribas A; Heller JB; Dissette VB; Glaspy JA; McBride WH; Economou JS
    Mol Immunol; 2000 Nov; 37(16):943-50. PubMed ID: 11395133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.
    Butterfield LH; Koh A; Meng W; Vollmer CM; Ribas A; Dissette V; Lee E; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 1999 Jul; 59(13):3134-42. PubMed ID: 10397256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination.
    Meng WS; Butterfield LH; Ribas A; Dissette VB; Heller JB; Miranda GA; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2001 Dec; 61(24):8782-6. PubMed ID: 11751399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
    Butterfield LH; Meng WS; Koh A; Vollmer CM; Ribas A; Dissette VB; Faull K; Glaspy JA; McBride WH; Economou JS
    J Immunol; 2001 Apr; 166(8):5300-8. PubMed ID: 11290817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.
    Liu Y; Daley S; Evdokimova VN; Zdobinski DD; Potter DM; Butterfield LH
    J Immunol; 2006 Jul; 177(1):712-21. PubMed ID: 16785570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
    Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
    Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy.
    Li Z; Gong H; Liu Q; Wu W; Cheng J; Mei Y; Chen Y; Zheng H; Yu X; Zhong S; Li Y
    Immunology; 2020 Apr; 159(4):384-392. PubMed ID: 31849039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.
    Butterfield LH; Ribas A; Dissette VB; Lee Y; Yang JQ; De la Rocha P; Duran SD; Hernandez J; Seja E; Potter DM; McBride WH; Finn R; Glaspy JA; Economou JS
    Clin Cancer Res; 2006 May; 12(9):2817-25. PubMed ID: 16675576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
    Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
    Front Immunol; 2020; 11():623. PubMed ID: 32425926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.
    Butterfield LH; Ribas A; Meng WS; Dissette VB; Amarnani S; Vu HT; Seja E; Todd K; Glaspy JA; McBride WH; Economou JS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5902-8. PubMed ID: 14676113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Tsuji H; Yamashita T; Kaneko S
    Int J Cancer; 2006 Mar; 118(5):1194-204. PubMed ID: 16152611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.
    Liu H; Xu Y; Xiang J; Long L; Green S; Yang Z; Zimdahl B; Lu J; Cheng N; Horan LH; Liu B; Yan S; Wang P; Diaz J; Jin L; Nakano Y; Morales JF; Zhang P; Liu LX; Staley BK; Priceman SJ; Brown CE; Forman SJ; Chan VW; Liu C
    Clin Cancer Res; 2017 Jan; 23(2):478-488. PubMed ID: 27535982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.
    Alisa A; Ives A; Pathan AA; Navarrete CV; Williams R; Bertoletti A; Behboudi S
    Clin Cancer Res; 2005 Sep; 11(18):6686-94. PubMed ID: 16166448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
    Docta RY; Ferronha T; Sanderson JP; Weissensteiner T; Pope GR; Bennett AD; Pumphrey NJ; Ferjentsik Z; Quinn LL; Wiedermann GE; Anderson VE; Saini M; Maroto M; Norry E; Gerry AB
    Hepatology; 2019 May; 69(5):2061-2075. PubMed ID: 30561769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel α-fetoprotein-derived helper T-lymphocyte epitope with strong immunogenicity in patients with hepatocellular carcinoma.
    Tamai T; Mizukoshi E; Kumagai M; Terashima T; Iida N; Kitahara M; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Honda M; Fushimi K; Kaneko S
    Sci Rep; 2020 Mar; 10(1):4021. PubMed ID: 32132566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization.
    Ayaru L; Pereira SP; Alisa A; Pathan AA; Williams R; Davidson B; Burroughs AK; Meyer T; Behboudi S
    J Immunol; 2007 Feb; 178(3):1914-22. PubMed ID: 17237442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.